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AbstrAct
The Cancer Genomics and Biology 2015 meeting embodied a three way 
collaboration among colleagues from the Global Cancer Genomics Consortium (GCGC), 
the Unifaith Cancer Institute China and Jiujiang University of China. The meeting 
marks the fifth and the last meeting of GCGC, which was formed in 2010. Previous 
four GCGC meetings have been held at the Tata Memorial Center- Mumbai, Institute 
of Molecular Medicine-Lisbon, and Graduate Medical School Kyoto University-Kyoto. 
In contrast to the genomic themes of the previous meetings, the 2015 conference 
theme was at the interface of laboratory and translation research and emerging 
therapeutics as reflected in the shared interests of all three collaborative entities – 
Cancer Genomics and Biology 2015. This year’s conference was co-organized by the 
Jiujiang University at the Run Run Shaw building, Jiujiang University, Jiujiang City, 
China, on November 13 and 14, 2015. The conference attracted over 174 participants 
with 13 platform presentations. Scientific sessions included a plenary and five platform 
scientific sessions with themes ranging from biomarkers, stem cells and markers 
of the tumor microenvironment, proteomics and epigenetics, big data, to hormone 
and expression profiles. The meeting concluded with closing remarks by conference 
co-chairs emphasizing with the need to broaden membership across the globe, 
establishing priorities, and redrafting a white paper to launch a new consortium. 
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IntroductIon
The recently concluded Cancer Genomics 
and Biology 2015 meeting (CGB 2015) embodied a 
meaningful collaboration among colleagues from the 
Global Cancer Genomics Consortium (GCGC), the 
Unifaith Cancer Institute and Jiujiang University from 
China. The meeting was particularly rewarding as it was 
to mark the 5th consecutive annual GCGC meeting but 
this time by spreading its wings to China by promoting 
collaborations in Cancer Genomics and Biology through 
three-ways partnership with the Unifaith Cancer Institute 
and Jiujiang University. The GCGC is an international 
organization founded by scientists, cryptographer, 
physician scientists and oncologists from five institutions – 
the School of Medicine and Health Sciences of the George 
Washington University, USA; the Kyoto University 
Graduate School of Medicine, Japan; the Rajiv Gandhi 
Center for Biotechnology, India; the Tata Memorial 
Centre, India; the Institute of Molecular Medicine, 
Hospital de Santa Maria, Portugal; and the Structural 
Genomic Consortium at the University of Oxford, UK. 
Previous four GCGC meetings have been held at the 
Tata Memorial Center- Mumbai, Institute of Molecular 
Medicine-Lisbon, and Graduate Medical School Kyoto 
University-Kyoto. The CGB 2015 was also special as 
it represented the last meeting of the GCGC which was 
formed in December 2010 for a period of five years. The 
meeting was also part of a new chapter with additional 
colleagues from around the globe by relaunching a 
modified consortium in 2016 to reflect changing horizons, 
the nature of scientific questions and available shared 
resources, and professional interests of our colleagues. 
This year’s conference was co-organized by the Jiujiang 
University at the Run Run Shaw building, Jiujiang 
University, Jiujiang City, China, on November 13 and 14, 
2015. The conference attracted over 10 overseas and 164 
Chinese domestic participants and included 13 invited 
platform presentations. 
Focus on the cancer Genomics, biology and 
cancer Patient care
In contrast to the genomic themes of the previous 
meetings, the 2015 conference theme was at the interface 
of laboratory and translation research and emerging 
therapeutics as reflected in the shared interests of all 
three collaborative entities – Cancer Genomics and 
Biology 2015. The conference was opened by its Co-
Chairman Professor Yao-fang Yang, Vice President 
Jiujiang University with a brief synopsis of the academic 
and scholarly activities and clinical medicine at the 
University. Prof. Yang also introduced the other two 
conference Co-Chairs Professor Louis Chow and 
Professor Rakesh Kumar, and highlighted the role played 
by newly developed research methodologies and cancer 
biology insights in medical education, training, research 
and clinical care at the Affiliated Hospital of Jiujiang 
University. Scientific sessions included a plenary and five 
platform scientific sessions with themes that included: 1) 
biomarkers; 2) two sessions on stem cells and markers 
of the tumor microenvironment; 3) proteomics and 
epigenetics; 4) big data; and 5) hormone and expression 
profiles. The meeting was concluded with closing remarks 
by Professors Chow, Kumar and Yang, and a discussion 
about the changing mission of the consortium, the need 
to integrate additional oncologists and cancer scientists 
across the world by re-drafting a consortium white paper, 
and discussed the venue and host of the 2016 meeting. 
biomarkers 
The meeting started with an opening plenary 
presentation on “Prognostic biomarkers in metastatic 
breast cancer” by Professor Luis Costa from Lisbon 
Medical Academic Center Portugal. Dr. Costa started 
by highlighting the value of understanding the most 
important limitations in the treatment of breast cancer - 
the development of resistance against most commonly 
used endocrine and HER2-directed therapies and 
associated predictive biomarkers. He presented data from 
the BOLERO-2 study showing that the combined use of 
mTOR inhibitor everolimus and exemestane in second 
line treatment of aromatase inhibitor resistant breast 
cancer lead to an increased time to progression, suggesting 
reversal of resistance. He also shared his own data showing 
a positive correlation between the levels of pS6 kinase, a 
biomarker of mTOR activity, with survival in metastatic 
BC patients [1]. Per Dr. Costa, inhibition of CDK4/6 by 
palbociclib is also effective in reversing or preventing 
endocrine resistance and increasing time to progression 
in metastatic breast cancer patients upon combining with 
the aromatase inhibitor letrozole. However, he pointed out 
that we do not have yet a biomarker to select the patients 
for CDK4/6 inhibition. Regarding resistance to HER2-
directed trastuzumab therapy, Dr. Costa reminded the 
audience of the unprecedented results of the CLEOPATRA 
study (i.e. superior overall survival when pertuzumab is 
added to trastuzumab and docetaxel) and the efficacy of 
T-DM1 for trastuzumab and lapainib resistant disease. 
Dr. Costa was also excited about the recently reported 
association of the high levels of stromal tumor-infiltrating 
lymphocytes with the lack of benefit from adjuvant 
trastuzumab but wondered about the validity of this finding 
in metastatic patients. Besides he shared recent findings 
from his lab showing an association between RANK’s 
missense SNPs and prognosis of breast cancer patients 
with bone metastases and suggested an increased overall 
survival of patients with homozygous polymorphisms 
compared to those with heterozygous ones [2]. Dr. Costa 
closed his presentation by emphasizing that there is a need 
to support clinical decisions with biomarkers as predictive 
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indicators of treatment response or resistance.
Professor Rakesh Kumar from the George 
Washington University started his plenary lecture by 
elaborating on the significance of extra- and intra-cellular 
milieu in modifying the genome through chromatin 
remodeling and specifically discussed the value of 
targeting the MTA1 master chromatin remodeler, one of 
the most frequently up-regulated oncogenes in human 
cancer [3]. MTA1 up-regulation correlates with an 
aggressive and invasive tumor phenotypes and unfavorable 
outcome for cancer patients. At the cellular level, MTA1-
containing chromatin remodeling complexes regulate a 
range of processes including, cell survival, invasiveness, 
transformation, DNA-damage response, angiogenesis, 
metastasis and therapeutic sensitivity of tumor cells. 
Dr. Kumar also discussed the role of MTA1-containing 
chromatin remodeling complexes as a hub to modify the 
expression of genes with functions in embryonic stem-
cell differentiation, reprogramming of pluripotent stem 
cells and mesenchymal as well as cancer stem cells. 
Furthermore, Dr. Kumar shared recent literature about the 
contribution of MTA1 in modifying the chemo-sensitivity 
of cancer cells in experimental model systems. Dr. Kumar 
also presented a brief summary of advances in the past 
two decades since the discovery of MTA1 and shared his 
view about the yet to be realized progress in the area of 
MTA1 in cancer biology and treatment. He concluded 
his presentation by highlighting the roles of signal-
dependent combinatorial post-translational modifications 
of MTA1 in determining the nature of resulting MTA1-
contaning chromatin remodeling complexes and selection 
of downstream target genes [4]. Finally, he discussed how 
selective recognition or targeting of such post-translational 
modifications of MTA1 could serve as superior biomarkers 
and targets in cancer.
Professor Da-Qiang Li from the Fudan University 
Shanghai Cancer Center highlighted the role of the ring-
between-ring (RBR) family of E3 ubiquitin ligases in 
breast cancer progression. He found that one of ring-
finger proteins (RNFs) is significantly down-regulated 
in human breast tumors as compared to its level in the 
matched adjacent noncancerous tissues, and predicts a 
better survival of breast cancer patients. Further analysis 
revealed that this molecule is largely silenced by DNA 
methylation of the putative CpG island and that treatment 
with the DNA methylation inhibitor or knockdown of the 
methyl-binding protein 4 (MBD4) activates the expression 
of this RNF. The remainder of Dr. Li’s presentation was 
focused on the underlying the nature of its downstream 
substrate(s) that might be responsible for the noted 
mechanism of action of this RNF in human cancer. 
Interestingly, Dr. Li was able to examine the status of this 
RNF as well as its putative substrate in primary breast 
cancer patients. Dr. Li concluded his presentation by 
establishing the significance of epigenetically silencing 
of a ligase in breast cancer progression and the value of 
various components of this pathway as biomarkers.
stem cells and Markers of tumor 
Microenvironment 
The highlights of the session included insightful 
discussion on the latest advances in Asian Cancer 
Genomics and their implication in our understanding 
and management of human cancer by Dr. Bin-Tean Teh 
from the National Cancer Center Singapore. The core of 
Dr. Teh approach resides in high-throughput technologies 
to ask complex yet relevant cancer genomic questions 
using the appropriate tumor specimens, and take these 
findings back to the patients by correlating them with 
clinicopathological variables and discover new therapeutic 
targets and biomarkers for the benefits of cancer patients. 
Dr. Teh used fibroepithelial breast tumors as an example 
to illustrate the approach taken by his team and how they 
discovered MED12 and RARA as frequently mutated 
genes in this group of tumors [5]. The second part of 
Dr. Teh’s presentation was focused on the genetics of 
pathogen- or no-pathogen driven cholangiocarcinomas, 
and its impact on pathogenesis of  the disease [6]. In 
the last segment of his presentation, Dr. Teh shared their 
very exciting studies on herbal carcinogenesis based on 
the association of Aristolochic Acid and the development 
of upper urinary tract urothelial cancer in certain Asian 
population. Finally, Dr. Teh highlighted the need to start 
using genomic biomarkers for screening individuals who 
might be susceptible to certain cancers.
Dr. Feng Gu from the Tianjin Medical University 
Cancer Institute and Hospital discussed the role of tumor 
microenvironment in tumor initiation and progression 
via supporting the cell proliferation, self-renewal 
capacity, immune evasion, and apoptotic resistance. In 
addition, he pointed out that the research of tumor should 
focus on a combined mechanism including the tumor 
microenvironment. Dr. Gu also discussed the merit of 
using a 3-D tumor model over 2-D cell culture system 
to simulate the tumor microenvironment using primary 
culture systems. He finished the discussion by focussing 
on multifactorial contribution of the network of tumor cell 
signaling and extracellular signaling in regulating cancer 
cell migration and metastasis.
Dr. Asha Nair from the Rajiv Gandhi Centre for 
Biotechnology Trivandrum discussed the contribution of 
cancer stem cells in the recurrence of colorectal cancer 
patients who have undergone surgical resection. The 
focus of her presentation was on the surgical margins and 
how one best can decide the optimal distal margin to be 
removed to minimize tumor recurrence. She argued that “a 
negative distal margin could be crucial for reducing risk of 
local and distant recurrence and post-surgery life of CRC 
patients.” In this context, Dr. Nair explored the molecular 
signatures and biomarkers that could be potentially used to 
make a decision about the resection length. Data presented 
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suggest the feasibility of collecting enriching cancer stem 
cell population, i.e. CD133, CD44, EpCAM positive, from 
clinical CRC specimens through FACS. The team found 
that distal surgical margins are enriched with EpCAM/
CD133 positive cells as compared to normal counterpart. 
Interestingly such cells in distal surgical margins also 
express drug resistance genes in some cases. Dr. Nair 
closed her presentation by suggesting that distal tumor 
margins may represent a safe niche for cancer stem cells 
and drug resistance cells – both important in disease 
recurrence. Therefore, Dr. Nair shared her experience in 
providing critical biomarker-based information to surgical 
oncologists to make an informed decision of the surgical 
length to be removed as they operate on CRC cancer 
patients.
Professor Xin-Yuan Guan from The University of 
Hong Kong presented a fascinating example of reversal 
of non-cancer stem cells into cancer stem cells by 
reprogramming through ATOH8 atonal helix-loop-helix 
transcription factor. He noted an overall ATOH8 down-
regulation in hepatocellular carcinomas and these events 
are associated with poor differentiation and disease-
free survival, and carried out functional study to show 
a tumor suppressive nature of ATOH8 [7]. Dr. Guan 
found that ATOH8 may be a board repressor of stemness-
associated genes such as OCT4, NANOG and CD133, and 
accordingly, the loss of ATOH8 in CD133+ cancer stem 
cell population with ability to self-renew, differentiate and 
resist chemotherapy. Consistent of these observations, Dr. 
Guan presented additional evidence showing that ATOH8 
depletion may lead to a better generation of induced 
pluripotent stem cells. In brief, Dr. Guan suggested that 
CD133 negative cells could be reprogrammed to destine 
into CD133+ cancer stem cells by modifying the levels of 
ATOH8; and conversely, ATOH8 expression may enhance 
the sensitivity of liver cancer cells to chemotherapy.
Proteomics and Epigenetics
Professor M. Radhakrishna Pillai from the Rajiv 
Gandhi Centre for Biotechnology highlighted the role 
of chemotherapy-induced emergence of drug resistance 
cells with cancer stem cells properties in controlling the 
therapeutic response versus failure. Dr. Pillai’s approach 
was focused on studying the biology of persister cells - 
surviving cell population after extremely high doses of 
chemotherapy. It appears that persister cells exhibit an 
increased autophagy and mitophagy as well as constitutive 
activation of redox masters. Dr. Pillai shared data 
establishing a quick shift in low proteasome activity at the 
onset of autophagy and that chronic mitophagy facilitate 
long term survival of resistant cells in low nutrient 
condition and intracellular protein stress. Over time, this 
population led to the generation cell populations with 
heterogeneous ROS and distinct tumorigenic potential. 
The second part of Dr. Pillai’s presentation was focused 
on understanding the dynamics of genes and proteins 
during the evolution of drug-resistance through decisive 
stages. Results from proteomics and transcriptomics 
analyses suggested that each cell state transition is 
generally marked with an unique cascades of signaling 
molecules and unusual stem cell markers, such as CD36, 
CD68, CD70 and heat shock proteins. Dr. Pillai suggested 
that increased intracellular inflammatory signaling 
simultaneously triggers autophagy dependent damage 
clearance during long cell cycle arrest while heat shock 
proteins and ubiquitin dependent pathway subsequently 
ensures emergence of few cells with altered intracellular 
protein network in delayed manner. 
Professor Li Zhu from the Shanghai Jiaotong 
University School of Medicine shared her experience in 
stratifying breast cancer patients based on the “primary 
prognostic predictors” such as tumor size, grade and 
lymph node status, HER2, estrogen receptor, and 
progesterone receptor (PgR) at the time of diagnosis. 
Dr. Zhu also discussed the evolution of the “secondary 
prognostic assays” which are expected to provide a 
better predictions of clinical outcome than the traditional 
clinical and pathological standards, because around 
50% of all recurrences in ER+ cancers develop after 
5 years, Dr. Zhu discussed the prognostic value of the 
newer tests (Prosigna™ , EndoPredict™ and BCI™) for 
late recurrences and identify specific group of patients 
might benefit from extended endocrine therapy. Dr. 
Zhu also shared the excitement associated with a recent 
gene expression-based outcome predictor for adjuvant 
chemotherapy and endocrine therapy sensitivity as the first 
example of a tertiary residual risk predictor. In brief, Dr. 
Zhu highlighted the significance of step-wise utilization of 
primary, secondary and tertiary prognostic endpoints in the 
treatment of breast cancer. 
big data
Professor Stefan Knapp from the University 
of Oxford and Johann Wolfgang Goethe-University 
discussed recent developments targeting bromodomains. 
In the first section of the talk he provided an overview on 
BET bromodomain inhibitors and the potential of these 
protein interaction inhibitors in the oncology field [8, 
9]. After this introduction he selected examples of non-
BET bromodomain inhibitors in particular inhibitors that 
target bromodomains present in SMARCA2/4 as well 
as CBP/EP300. Both of these bromodomain inhibitors 
are non-toxic to cancer cells. However, inhibition of 
SMARCA2/4 bromodomains mediates expression of 
key genes important for certain cell differentiation.
Interestingly, CBP/EP300 bromodomain inhibition affects 
leukemia inducing cells (LICs) resulting in differentiation 
and induction of apoptosis. In addition, CBP/EP300 
bromodomain inhibitors are synergistic with doxorubicine 
as well as BET inhibition suggesting that combination 
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studies or CBP/BET dual inhibitors may lead to better 
efficacy in leukemia and potentially in other cancers.
Dr. Masahiro Sugimoto from the Institute for 
Advanced Biosciences at Keio University presented his 
work about the development of a mathematical algorithm 
which could be used to predict the outcome of neoadjuvant 
chemotherapy for HER2 positive breast cancer and how 
he got involved in such research questions. Neoadjuvant 
chemotherapy is generally used the reduction of tumor 
size, and pathological complete response (pCR) post- 
neoadjuvant chemotherapy is viewed as a prognosis 
marker. Dr. Sugimoto highlighted the poor predictive 
accuracy of pCR in neoadjuvant setting using trastuzumab, 
and the need to develop a novel mathematical model based 
on artificial intelligence to realize better accuracy than 
conventional statistical approaches. He also discussed the 
steps taken to validate the model using a dataset involving 
776 breast cancer patients. He shared his hope that such 
a model would contribute to the personalization of the 
neoadjuvant chemotherapy treatments.
Hormone Expression Profiles
Professor Louis Chow from the Macau University of 
Science, Technology and Organisation for Oncology and 
Translational Research and Jiujiang University discussed 
emerging targeted treatment modalities for breast cancer 
[10]. He started by comparing the traditional, clinical 
risk factors for breast cancer patients with several novel 
molecular arrays that may help determine recurrence risk. 
Dr. Chow provided an overview on the current different 
risk-arrays, largely for luminal breast tumors. PAM-
50™, Oncotype DX™, Mammaprint™, BreastPRS™, 
EndoPredict™ and Mammostrat™ are all breast cancer 
risk assessment arrays and Dr. Chow inter-compared these 
different arrays for gene panels, methodology, timing and 
patient selection to optimise array utilization. Dr. Chow 
continued to discuss breast cancer subtypes, noting that 
Triple Negative Breast Cancers (TNBC) have recently 
been further sub classified into six distinctly separate 
subtypes, responsive to different classes of drugs. TNBC 
should no longer be regarded as one molecular group. 
Dr. Chow continued his presentation by highlighting 
the need of better methods to monitor tumor molecular 
changes over time and discussed the liquid biopsy, thereby 
stressing tumor heterogeneity. He ended his presentation 
by seeking a better bi-directional interactions between 
clinicians and laboratory scientists and continuing the 
development of technologies such as liquid biopsies.
Dr. Amit Dutt from the Tata Memorial Centre 
discussed the nature of genomic and molecular changes 
associated with the events in the surrounding tissues of 
breast cancer patients undergoing surgery. The study 
was undertaken to address a broader question about the 
transcriptomic status of breast tumors in patients who opt 
to undergo surgical intervention which is also known to 
trigger perioperative hypoxia. Dr. Dutt started with the 
study design involving transcriptomic analyses of breast 
tumors collected at distinct presumed hypoxic stages. He 
also discussed the status of various regulatory networks 
as emerged from the study. Dr. Dutt finished his lecture 
by suggesting that targeting one or more of these nodules 
during perioperative surgery may influence the clinical 
outcome of breast cancer patients undergoing surgical 
intervention.
conclusIons
In summary, the conference was two full days of 
scientific celebration of ideas and discussions of recent 
advances in cancer genomic biology, therapeutics, and 
treatment. Most of the questions and answers segments 
were dominated by discussing how to take forward 
the findings to the bedside and what should be done to 
maintain the momentum gained at this and preceding four 
meetings. Another distinctive feature of the meeting was 
an active participation of medical educators and professors 
and medical students. It was not uncommon to witness 
questions from practicing clinicians and educators relating 
the scientific presentations with their teaching and training 
responsibilities. Keeping in-line of the past four meetings, 
issues surrounding the value of tumor heterogeneity 
and transcriptome and how to design start anti-cancer 
agents echoed throughout the conference. As expected, 
scientific sessions started with an overview of the field, 
what’s emerging, what are the current limitations, and 
how one can take the research question forward in the 
overall interest of cancer biology and treatment. Finally, 
in the closing remarks by conference Co-Chairs, the group 
discussed about the nature of feasible activities within the 
changing framework of consortium members and use of 
tele-medicine for the benefits of cancer patients. 
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Presented at the Run Run Shaw building, Jiujiang 
University, Jiujiang, China; November 13-14, 2015.
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